logo-loader

Theratechnologies a star player, Eguana capitalizing on design wins

Published: 15:46 18 Aug 2016 EDT

Theratechnologies health therapy heading into Phase-3 testing looks promising

Analysts from Mackie Research gave Theratechnologies Inc. (TSE:TH) a buy rating with a target of C$4.40, up from C$2.50 on Thursday.

The broker called the company a future star player and cited good prospects for Theratechnologies’ sales of ibalisumab, an antibody that inhibits HIV infection.

"The infectious disease week conference is a key spot to highlight new data for an HIV drug." wrote Andre Uddin, Mackie analyst. "With no safety issues previously shown for ibalizumab and knowing that the primary endpoint hit, we believe this should be an exciting new product launch in 2017 for an HIV patient population with few treatment options."

Mackie also gave Eguana Technologies Inc. (CVE:EGT) a speculative buy rating and a target of C$0.70, up from C$0.40, noting that recent design wins and predicted revenue conversion could support greater stock price appreciation.

Dundee gave a neutral, medium-risk rating to Allied Properties REIT (TSE:AP.UN), slightly downgrading its target to C$38.27 from C$38.50. While Allied’s balance sheet seems to be improving and debt went down, the volume of acquisitions for the company could soon be lower.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 47 minutes ago